Early data shows mRNA-4359 may benefit patients with advanced solid cancers
Interim Phase I data of mRNA-4359 immunotherapy shows promise in advanced solid cancers, with 8/16 patients showing no tumor growth. The therapy activates immune response and is well-tolerated, supporting further research.
Highlighted Terms
Related News
Early data shows mRNA-4359 may benefit patients with advanced solid cancers
Interim Phase I data of mRNA-4359 immunotherapy shows promise in advanced solid cancers, with 8/16 patients showing no tumor growth. The therapy activates immune response and is well-tolerated, supporting further research.